Last reviewed · How we verify
anti-CEA CAR-T cells
At a glance
| Generic name | anti-CEA CAR-T cells |
|---|---|
| Also known as | Designer T cells, Gene modified patient T cells, SureFire Precision Infusion System, K171355, TriSalus PEDD |
| Sponsor | Roger Williams Medical Center |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors (PHASE1)
- Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer (PHASE1)
- A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors (PHASE1)
- Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma (PHASE1)
- An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors (PHASE1)
- Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases (PHASE1)
- CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) (PHASE1)
- Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-CEA CAR-T cells CI brief — competitive landscape report
- anti-CEA CAR-T cells updates RSS · CI watch RSS
- Roger Williams Medical Center portfolio CI